他汀类降血脂药物的药代动力学研究进展

摘要/Abstract

摘要： 他汀类药物, 即β-羟甲基戊二酰单酰辅酶A(HMG-CoA)还原酶抑制剂, 是广泛应用于临床的公认的高效降脂药。其降脂作用是通过抑制HMGCoA还原酶(胆固醇合成途径的限速酶), 从而抑制胆固醇的合成, 使血液中总胆固醇及低密度脂蛋白胆固醇(LDL-C)含量下降。其预防心血管疾病的作用已经过大量临床试验证实。然而, 他汀类药物的肌肉毒性副作用也呈现剂量相关性, 包括肌病或横纹肌溶解症, 在一些病例中这类毒性作用相当严重,已经证实这些毒性作用与他汀类药物的药物代谢动力学改变相关。基于以往的研究, 我们可以推测在联合服用其他药物后的他汀类药物的药动学改变,或者是推测当病人的他汀类药物代谢率降低或者相关转运体功能下降后, 他汀类药物的药代动力学改变。为了尽可能地掌握药代动力学的改变规律和机理, 我们需要与他汀类药物相关的代谢酶和转运体的信息。本文重点从遗传药理学的角度, 综述了他汀类药物的药代动力学相关信息和理化特性, 从而利于我们更好地理解影响他汀类药物药动学和药效学改变的主要机制。

关键词: 他汀类药物, β-羟甲基戊二酰单酰辅酶A还原酶抑制剂, 转运体, 遗传药理学

Abstract: Statins are kinds of 3-Hydroxy-3-methylglutaryl coenzyme A (HMG-CoA)reductase inhibitors and are widely used for the treatment of hypercholesterolemia. Their efficacy in preventing cardiovascular events has been confirmed by a large number of clinical trials.However, muscular side effects, sometimes severe, including myopathy or rhabdomyolysis, are dose-dependent and associated with the pharmacokinetic alterations of statins. Based on previous studies, pharmacokinetic alterations of statins can be predicted following coadministration of other drugs or in patients with lowered activities in drug metabolism and or transport.To understand the mechanism of the pharmacokinetic alteration, we need the information about the metabolizing enzyme(s)and transporter(s)involved in the pharmacokinetics of statins.In this review, the pharmacokinetic aspects and physicochemical properties of statins are reviewed in order to understand the mechanism governing their pharmacokinetic alterations.

Key words: statins, 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, transporter, pharmacogenetics

中图分类号:

R968
R969.1

邓建伟, 郭栋, 周宏灏. 他汀类降血脂药物的药代动力学研究进展[J]. 中国临床药理学与治疗学, 2007, 12(8): 850-860.

DENG Jian-wei, GUO Dong, ZHOU Hong-hao. Pharmacokinetics research progress on statins[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2007, 12(8): 850-860.

参考文献

1 Sacks FM, Pfeffer MA, Moye LA, et al.The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels.Cholesterol and Recurrent Events Trial investigators[J].N Engl J Med, 1996;335:1001-1009.
2 Bertolini S, Bon GB, Campbell LM, et al.Efficacy and safety of atorvastatin compared to pravastatin in patients with hypercholesterolemia[J].Atherosclerosis, 1997;130:191-197.
3 Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels.The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID)Study Group[J].N Engl JMed, 1998;339:1349-1357.
4 Staffa JA, Chang J, Green L.Cerivastatin and reports of fatal rhabdomyolysis[J].N Engl J Med, 2002;346:539-540.
5 Thompson PD, Clarkson P, Karas RH.Statin-associated myopathy[J].JAMA, 2003;289:1681-1690.
6 Pierce LR,Wysowski DK,Gross TP.Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy [J].Jama, 1990;264:71-75.
7 Pogson GW, Kindred LH, Carper BG.Rhabdomyolysis and renal failure associated with cerivastatin-gemfibrozil combination therapy[J].Am J Cardiol, 1999;83:1146.
8 Backman JT, Kyrklund C, Neuvonen M, et al.Gemfibrozil greatly increases plasma concentrations of cerivastatin[J].Clin Pharmacol Ther, 2002;72:685-691.
9 Alberts AW, Chen J, Kuron G, et al.Mevinolin:a highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase and a cholesterol-lowering agent[J].Proc Natl Acad Sci USA, 1980;77:3957-3961.
10 Hoffman WF, Alberts AW, Anderson PS, et al.3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors.4.Side chain ester derivatives of mevinolin[J].J Med Chem, 1986;29:849-852.
11 Endo A.The discovery and development of HMG-CoA reductase inhibitors[J].J Lipid Res, 1992;33:1569-1582.
12 Kajinami K, Masuy a H, Hoshiba Y, et al.Statin response and pharmacokinetics variants [J].Expert Opin Pharmacother, 2005;6:1291-1297.
13 NiemiM, Schaeffeler E, Lang T, et al.High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1)[J].Pharmacogenetics, 2004;14:429-440.
14 Wang A, Yu BN, Luo CH, et al.Ile118Val genetic polymorphism of CYP3A4 and its effects on lipid-lowering efficacy of simvastatin in Chinese hyperlipidemic patients[J].Eur J Clin Pharmacol, 2005;60:843-848.
15 Kajinami K, Takekoshi N, BrousseauME, et al.Pharmacogenetics of HMG-CoA reductase inhibitors:exploring the potential for genotype-based individualization of coronary heart disease management[J].Atherosclerosis, 2004;177:219-234.
16 IshigamiM, Honda T, Takasaki W, et al.A comparison of the effects of 3-hydroxy-3-methylglutaryl-coenzyme a (HMG-CoA) reductase inhibitors on the CYP3A4-dependent oxidation of mexazolam in vitro[J].Drug Metab Dispos, 2001;29:282-288.
17 Hirano M, Maeda K, Matsushima S, et al.Involvement of BCRP(ABCG2)in the biliary excretion of pitavastatin[J].Mol Pharmacol, 2005;68:800-807.
18 Holdgate GA,WardWH, McTaggart F.Molecular mechanism for inhibition of 3-hydroxy-3-methylglutaryl CoA (HMG-CoA) reductase by rosuvastatin[J].Biochem Soc Trans, 2003;31:528-531.
19 Backman JT, Kyrklund C, Kivisto KT, et al.Plasma concentrations of active simvastatin acid are increased by gemfibrozil [J].Clin Pharmacol Ther, 2000;68:122-129.
20 Kivisto KT, Kantola T, Neuvonen PJ.Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin [J].Br J Clin Pharmacol, 1998;46:49-53.
21 Ky rklund C, Backman JT, Kivisto KT, et al.Plasma concentrations of active lovastatin acid are markedly increased by gemfibrozil but not by bezafibrate[J].Clin Pharmacol Ther, 2001; 69:340-345.
22 Cooper KJ, Martin PD, Dane AL, et al.Effect of itraconazole on the pharmacokinetics of rosuvastatin[J].Clin Pharmacol Ther, 2003;73:322-329.
23 Klotz U.Pharmacological comparison of the statins[J].Arzneimittelforschung, 2003;53:605-611.
24 Martin PD, WarwickMJ, Dane AL, et al.Metabolism, excretion, and pharmacokinetics of rosuvastatin in healthy adult male volunteers[J].Clin Ther, 2003;25:2822-2835.
25 Schneck DW, Birmingham BK, Zalikowski JA, et al.The effect of gemfibrozil on the pharmacokinetics of rosuvastatin[J]. Clin Pharmacol Ther, 2004;75:455-463.
26 Schachter M.Chemical, pharmacokinetic and pharmacodynamic properties of statins:an update[J].Fundam Clin Pharmacol, 2005;19:117-125.
27 Yamazaki M, Tokui T, IshigamiM, et al.Tissue-selective uptake of pravastatin in rats:contribution of a specific carrier-mediated uptake system[J].Biopharm Drug Dispos, 1996;17:775-789.
28 Yamazaki M, Akiyama S, Ni'inuma K, et al.Biliary excretion of pravastatin in rats:contribution of the excretion pathway mediated by canalicular multispecific organic anion transporter [J].Drug Metab Dispos, 1997;25:1123-1129.
29 Hsiang B, Zhu Y, Wang Z, et al.A novel human hepatic organic anion transporting polypeptide (OATP2).Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters[J].J Biol Chem, 1999;274: 37161-37168.
30 Sirtori CR.Tissue selectivity of hydroxymethylglutaryl coenzyme A (HMG CoA) reductase inhibitors [J].Pharmacol Ther, 1993;60:431-459.
31 Sasaki M, Suzuki H, Ito K, et al.Transcellular transport of organic anions across a double-transfected Madin-Darby canine kidney II cell monolayer expressing both human organic aniontransporting polypeptide (OATP2 SLC21A6)and Multidrug resistance-associated protein 2 (MRP2 ABCC2)[J].J Biol Chem, 2002;277:6497-6503.
32 Hirano T, Ishikawa K, Mii M.Cryopreservation of immature seeds of Ponerorchis graminifolia var.suzukiana by vitrification [J].Cryo Letters, 2005;26:139-146.
33 Transon C, Leemann T, Vogt N, et al.In vivo inhibition profile of cytochrome P450TB (CYP2C9)by (+-)-fluvastatin [J].Clin Pharmacol Ther, 1995;58:412-417.
34 Transon C, Leemann T, Dayer P.In vitro comparative inhibition profiles of major human drug metabolising cytochrome P450 isozymes (CYP2C9, CYP2D6 and CYP3A4)by HMG-CoA reductase inhibitors[J].Eur J Clin Pharmacol, 1996;50:209-215.
35 Tsuji A.Tissue selective drug delivery utilizing carrier-mediated transport systems[J].J Control Release, 1999;62:239-244.
36 Lennernas H.Clinical pharmacokinetics of atorvastatin[J]. Clin Pharmacokinet, 2003;42:1141-1160.
37 Takeda M, Noshiro R, Onozato ML, et al.Evidence for a role of human organic anion transporters in the muscular side effects of HMG-CoA reductase inhibitors[J].Eur J Pharmacol, 2004; 483:133-138.
38 Lau YY, Okochi H, Huang Y, et al.Multiple transporters affect the disposition of atorvastatin and its two active hydroxy metabolites: application of in vitro and ex situ systems[J].J Pharmacol Exp Ther, 2006;316:762-771.
39 Mwinyi J, Johne A, Bauer S, et al.Evidence for inverse effects of OATP-C(SLC21A6)5 and 1b haplotypes on pravastatin kinetics[J].Clin Pharmacol Ther, 2004;75:415-421.
40 Nozawa T, Nakajima M, Tamai I, et al.Genetic polymorphisms of human organic anion transporters OATP-C (SLC21A6)and OATP-B (SLC21A9):allele frequencies in the Japanese population and functional analy sis[J].J Pharmacol Exp Ther, 2002;302:804-813.
41 Michalski C, Cui Y, Nies AT, et al.A naturally occurring mutation in the SLC21A6 gene causing impaired membrane localization of the hepatocyte uptake transporter[J].J Biol Chem, 2002;277:43058-43063.
42 Iwai M, Suzuki H, Ieiri I, et al.Functional analysis of single nucleotide polymorphisms of hepatic organic anion transporter OATP1B1 (OATP-C)[J].Pharmacogenetics, 2004;14:749-757.
43 Jokubaitis LA.Updated clinical safety experience with fluvastatin[J].Am J Cardiol, 1994;73:18D-24D.

[1]	郝潇, 赵美, 王文静, 张飞飞, 刘惠良, 党懿, 李树仁, 齐晓勇. 钠-葡萄糖共转运体2抑制剂在急性心肌梗死应用研究进展[J]. 中国临床药理学与治疗学, 2023, 28(7): 824-831.
[2]	赵璐, 李付勇, 温滨红, 李道伟. 他汀类药物治疗伴高脂血症偏头痛患者的临床疗效分析[J]. 中国临床药理学与治疗学, 2023, 28(6): 671-675.
[3]	潘淑, 吴义金, 张洒洒, 王启海, 罗婷婷, 殷勤. 基于OAT3介导的MTX治疗佐剂诱导性关节炎大鼠的药动学研究[J]. 中国临床药理学与治疗学, 2022, 27(5): 516-525.
[4]	陈佳音, 王丽, 王立军, 童刚领, 马洁, 陈西敬, 卢杨. 有机阳离子转运体基因多态性与奥沙利铂毒性及疗效的相关性研究[J]. 中国临床药理学与治疗学, 2022, 27(2): 171-177.
[5]	刘璐, 陈笑艳. 国产小分子化学创新药临床药物相互作用研究现状[J]. 中国临床药理学与治疗学, 2021, 26(8): 863-875.
[6]	孟强, 刘克辛. 转运体介导药物相互作用的研究现状及展望[J]. 中国临床药理学与治疗学, 2021, 26(8): 876-888.
[7]	周晗, 刘晓东. 生理药代动力学模型在创新药物评价中应用及其若干问题的思考[J]. 中国临床药理学与治疗学, 2021, 26(8): 889-913.
[8]	张远金, 黄盛博, 刘洁, 王昕. 药物代谢创新模型：基因编辑大鼠和小肠3D类器官[J]. 中国临床药理学与治疗学, 2021, 26(8): 914-922.
[9]	鲁琼, 朱海宏, 戚听听, 李国华, 滕欣琪, 屈强, 屈健. OCTN2基因多态性影响结直肠癌奥沙利铂化疗敏感性[J]. 中国临床药理学与治疗学, 2021, 26(4): 401-407.
[10]	王凤玲, 孟祥云, 陈正徐, 曹荣娟, 何争民, 叶茜, 王聪, 李琪. 安徽地区汉族心血管疾病患者SLCO1B1与ApoE基因多态性分布及其在他汀类药物临床个体化应用中的意义[J]. 中国临床药理学与治疗学, 2021, 26(1): 40-48.
[11]	钟凯龙, 王永胜, 陈方, 叶岩荣. 基于血脑屏障转运体的中枢神经系统疾病治疗策略探讨与展望#br#[J]. 中国临床药理学与治疗学, 2020, 25(8): 953-960.
[12]	李丹云, 牛培广, 史道华 . 基于谷氨酰胺代谢抗肿瘤药物的研究进展[J]. 中国临床药理学与治疗学, 2020, 25(7): 810-816.
[13]	沙碧君，周素凤，王璐，赵玉清，陈西敬，邵凤. 药物相互作用临床研究方法及进展[J]. 中国临床药理学与治疗学, 2019, 24(9): 1037-1045.
[14]	林敏，沈仲夏，钱敏才，崔力军，任列，蔡敏，沈鑫华. 5-羟色胺转运体基因多态性与抗抑郁剂治疗广泛性焦虑障碍疗效的关联[J]. 中国临床药理学与治疗学, 2019, 24(8): 903-909.
[15]	陈泓竹，刘建明，周芳，贾元威，王广基，张经纬. 内源性物质代谢对药物代谢处置的影响及机制研究[J]. 中国临床药理学与治疗学, 2019, 24(5): 580-588.